PortalPublikationenP53 overexpression and Ki67-index are associated with outcom...

P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment

Standard

P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. / Striefler, Jana K; Sinn, Marianne; Pelzer, Uwe; Jühling, Anja; Wislocka, Lilianna; Bahra, Marcus; Sinn, Bruno V; Denkert, Carsten; Dörken, Bernd; Oettle, Helmut; Riess, Hanno; Bläker, Hendrik; Lohneis, Philipp.

in: PATHOL RES PRACT, Jahrgang 212, Nr. 8, 08.2016, S. 726-34.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Striefler, JK, Sinn, M, Pelzer, U, Jühling, A, Wislocka, L, Bahra, M, Sinn, BV, Denkert, C, Dörken, B, Oettle, H, Riess, H, Bläker, H & Lohneis, P 2016, 'P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment', PATHOL RES PRACT, Jg. 212, Nr. 8, S. 726-34. https://doi.org/10.1016/j.prp.2016.06.001

APA

Striefler, J. K., Sinn, M., Pelzer, U., Jühling, A., Wislocka, L., Bahra, M., Sinn, B. V., Denkert, C., Dörken, B., Oettle, H., Riess, H., Bläker, H., & Lohneis, P. (2016). P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. PATHOL RES PRACT, 212(8), 726-34. https://doi.org/10.1016/j.prp.2016.06.001

Vancouver

Striefler JK, Sinn M, Pelzer U, Jühling A, Wislocka L, Bahra M et al. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. PATHOL RES PRACT. 2016 Aug;212(8):726-34. https://doi.org/10.1016/j.prp.2016.06.001

Bibtex

@article{5a3cbf5acc334d55bf130795e233b598,
title = "P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment",
abstract = "In pancreatic cancer there is a need for prognostic risk stratification and subsequent therapy strategies. Molecular analysis has shown in different cancers that variation in clinical behavior can be associated with specific alterations. The cell cycle regulators p16 and p53 belong to the most often alterated genes in pancreatic ductal adenocarcinoma (PDAC). We analyzed protein expression of p16, p53 and Ki67 by immunohistochemistry in 162 tumours of the CONKO-001 trial that investigated the role of adjuvant gemcitabine in pancreatic cancer patients. We could show that high proliferation of tumours and strong and consistent nuclear p53 expression by tumour cells is associated with a worse disease-free survival and overall survival in the overall study population. However, stratified analysis according to treatment arm revealed that the effect of deregulated p53 expression and high Ki67 expression was restricted to the disease free survival of patients treated with adjuvant gemcitabine. In multivariable survival analysis, p53 did not retain its prognostic status. Our study supports the important role of p53 and Ki67 expression in PDAC. They provide prognostic information in patients with adjuvant gemcitabine treatment and may contribute to treatment decision. However, these results should be validated in further studies. ",
keywords = "Aged, Antimetabolites, Antineoplastic/therapeutic use, Carcinoma, Pancreatic Ductal/drug therapy, Chemotherapy, Adjuvant, Cyclin-Dependent Kinase Inhibitor p16/metabolism, Deoxycytidine/analogs & derivatives, Disease-Free Survival, Female, Humans, Immunohistochemistry, Ki-67 Antigen/metabolism, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms/drug therapy, Prognosis, Survival Rate, Treatment Outcome, Tumor Suppressor Protein p53/metabolism, Up-Regulation",
author = "Striefler, {Jana K} and Marianne Sinn and Uwe Pelzer and Anja J{\"u}hling and Lilianna Wislocka and Marcus Bahra and Sinn, {Bruno V} and Carsten Denkert and Bernd D{\"o}rken and Helmut Oettle and Hanno Riess and Hendrik Bl{\"a}ker and Philipp Lohneis",
note = "Copyright {\textcopyright} 2016 Elsevier GmbH. All rights reserved.",
year = "2016",
month = aug,
doi = "10.1016/j.prp.2016.06.001",
language = "English",
volume = "212",
pages = "726--34",
journal = "PATHOL RES PRACT",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "8",

}

RIS

TY - JOUR

T1 - P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment

AU - Striefler, Jana K

AU - Sinn, Marianne

AU - Pelzer, Uwe

AU - Jühling, Anja

AU - Wislocka, Lilianna

AU - Bahra, Marcus

AU - Sinn, Bruno V

AU - Denkert, Carsten

AU - Dörken, Bernd

AU - Oettle, Helmut

AU - Riess, Hanno

AU - Bläker, Hendrik

AU - Lohneis, Philipp

N1 - Copyright © 2016 Elsevier GmbH. All rights reserved.

PY - 2016/8

Y1 - 2016/8

N2 - In pancreatic cancer there is a need for prognostic risk stratification and subsequent therapy strategies. Molecular analysis has shown in different cancers that variation in clinical behavior can be associated with specific alterations. The cell cycle regulators p16 and p53 belong to the most often alterated genes in pancreatic ductal adenocarcinoma (PDAC). We analyzed protein expression of p16, p53 and Ki67 by immunohistochemistry in 162 tumours of the CONKO-001 trial that investigated the role of adjuvant gemcitabine in pancreatic cancer patients. We could show that high proliferation of tumours and strong and consistent nuclear p53 expression by tumour cells is associated with a worse disease-free survival and overall survival in the overall study population. However, stratified analysis according to treatment arm revealed that the effect of deregulated p53 expression and high Ki67 expression was restricted to the disease free survival of patients treated with adjuvant gemcitabine. In multivariable survival analysis, p53 did not retain its prognostic status. Our study supports the important role of p53 and Ki67 expression in PDAC. They provide prognostic information in patients with adjuvant gemcitabine treatment and may contribute to treatment decision. However, these results should be validated in further studies.

AB - In pancreatic cancer there is a need for prognostic risk stratification and subsequent therapy strategies. Molecular analysis has shown in different cancers that variation in clinical behavior can be associated with specific alterations. The cell cycle regulators p16 and p53 belong to the most often alterated genes in pancreatic ductal adenocarcinoma (PDAC). We analyzed protein expression of p16, p53 and Ki67 by immunohistochemistry in 162 tumours of the CONKO-001 trial that investigated the role of adjuvant gemcitabine in pancreatic cancer patients. We could show that high proliferation of tumours and strong and consistent nuclear p53 expression by tumour cells is associated with a worse disease-free survival and overall survival in the overall study population. However, stratified analysis according to treatment arm revealed that the effect of deregulated p53 expression and high Ki67 expression was restricted to the disease free survival of patients treated with adjuvant gemcitabine. In multivariable survival analysis, p53 did not retain its prognostic status. Our study supports the important role of p53 and Ki67 expression in PDAC. They provide prognostic information in patients with adjuvant gemcitabine treatment and may contribute to treatment decision. However, these results should be validated in further studies.

KW - Aged

KW - Antimetabolites, Antineoplastic/therapeutic use

KW - Carcinoma, Pancreatic Ductal/drug therapy

KW - Chemotherapy, Adjuvant

KW - Cyclin-Dependent Kinase Inhibitor p16/metabolism

KW - Deoxycytidine/analogs & derivatives

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Ki-67 Antigen/metabolism

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Pancreatic Neoplasms/drug therapy

KW - Prognosis

KW - Survival Rate

KW - Treatment Outcome

KW - Tumor Suppressor Protein p53/metabolism

KW - Up-Regulation

U2 - 10.1016/j.prp.2016.06.001

DO - 10.1016/j.prp.2016.06.001

M3 - SCORING: Journal article

C2 - 27461834

VL - 212

SP - 726

EP - 734

JO - PATHOL RES PRACT

JF - PATHOL RES PRACT

SN - 0344-0338

IS - 8

ER -